Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company usually posts poor financials for mid or long term investments.
Strengths
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The group usually releases upbeat results with huge surprise rates.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The tendency within the weekly time frame is positive above the technical support level at 14.19 EUR
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at EUR 22.42.
  • The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company has insufficient levels of profitability.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • Based on current prices, the company has particularly high valuation levels.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
ABLYNX86.59%1 802
CELLTRION, INC.--.--%23 699
IQVIA HOLDINGS INC32.70%21 261
INCYTE CORPORATION-3.68%20 703
LONZA GROUP57.44%20 102
ALNYLAM PHARMACEUTICALS, IN..249.60%12 278
NEKTAR THERAPEUTICS339.85%8 917
ALKERMES PLC-4.86%8 035
SEATTLE GENETICS, INC.12.30%8 018
QIAGEN NV7.36%7 398
SAGE THERAPEUTICS INC227.73%6 760
IONIS PHARMACEUTICALS INC14.15%6 662
EXACT SCIENCES CORPORATION302.92%6 212
ICON PLC47.79%6 154
UNITED THERAPEUTICS CORPORA..-5.03%5 889
PRA HEALTH SCIENCES INC48.04%5 528
More Results
Financials (€)
Sales 2017 64,7 M
EBIT 2017 -56,2 M
Net income 2017 -73,4 M
Finance 2017 203 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 20,4x
EV / Sales 2018 23,6x
Capitalization 1 524 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ABLYNX
Duration : Period : Day
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Duration : Period : Week
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders